Olga Merino

Publications (2)7.42 Total impact

• Source

  Available from: Tiago Nunes

  Article: High smoking cessation rate in Crohn's disease patients after physician advice - The TABACROHN Study.

  Tiago Nunes, Maria Josefina Etchevers, Olga Merino, Sonia Gallego, Valle García-Sánchez, Ignacio Marín-Jiménez, Luis Menchén, Manuel Barreiro-de Acosta, Guillermo Bastida, Sara García, [......], Eva Martí, Fernando Gomollón, Maite Arroyo, David Monfort, Esther García-Planella, Benito Gonzalez, Carme Loras, Carles Agustí, Carolina Figueroa, Miquel Sans
  [show abstract] [hide abstract]
  ABSTRACT: INTRODUCTION: Tobacco smoking has a significant impact on the development of Crohn's disease (CD) and its clinical course, making smoking cessation one of the main goals in CD therapeutic strategy. AIMS: To evaluate the effectiveness of an advice-based smoking cessation strategy among CD patients. METHODS: We have performed a prospective multicenter study which enrolled 408 CD smokers. At inclusion all patients were instructed about the risks of smoking and subsequently followed every 3months. Each center used additional smoking cessation strategies based on available resources. Urinary cotinine and exhaled carbon monoxide levels were evaluated in a subgroup of patients. RESULTS: Median study follow up was 18 months. 31% of the patients achieved complete smoking cessation and 23% were smoking-free at the end of their follow up with 8% of smoking relapse. Most patients not achieving smoking cessation did not change their smoking habit with only 5% presenting a decrease in tobacco load. 63% of patients willing to quit smoking received help from another specialist, most frequently the pulmonologist (47%). Surprisingly, most patients (88%) tried to quit smoking with no pharmacological therapy and bupropion, varenicline and nicotine replacement treatment were used in few patients. Urinary cotinine and exhaled CO levels tested in a subgroup of patients proved to have a good correlation with the self-reported smoking habit. No predictors of successful smoking cessation were identified. CONCLUSION: Our results underline that an anti-tobacco strategy mostly based on CD patients´s education and counseling is feasible and effective in helping patients reach complete abstinence.
  Journal of Crohn s and Colitis 05/2012; · 2.57 Impact Factor
• Source

  Available from: Tiago Nunes

  Article: Does smoking influence Crohn's disease in the biologic era? The tabacrohn study.

  Tiago Nunes, Maria Josefina Etchevers, Olga Merino, Sonia Gallego, Valle García-Sánchez, Ignacio Marín-Jiménez, Luis Menchén, Manuel Barreiro-de Acosta, Guillermo Bastida, Sara García, [......], Daniel Ginard, Fernando Gomollón, Maite Arroyo, David Monfort, Esther García-Planella, Benito Gonzalez, Carme Loras, Carles Agustí, Carolina Figueroa, Miquel Sans
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: While most studies have found a negative effect of smoking on Crohn's disease (CD) phenotype, more recent data have failed to reproduce this association, which might be due to a current wider use of thiopurines and biologic therapy. The TABACROHN study aimed at defining the impact of smoking on CD in the largest published series. METHODS: This multicenter cross-sectional study included 1170 CD patients. Patients were classified as nonsmokers, current smokers, or former smokers according to their present smoking status. Clinical data regarding disease characteristics, treatment, and complications were collected. RESULTS: Smokers were more frequently under maintenance treatment when compared to nonsmokers. In addition, current smokers presented higher use of biologic drugs compared to nonsmokers. Tobacco exposure and a higher tobacco load were independent predictors of need for maintenance treatment and stenosing phenotype, respectively. CONCLUSIONS: In the era of early and widespread use of immunosuppressants and biologics, tobacco exposure is an independent predictor of need for maintenance treatment, specifically biologic therapy. The wider use of biologics and immunosuppressants could account for the existence of no major differences in disease behavior and complications between nonsmokers and current smokers. (Inflamm Bowel Dis 2012;).
  Inflammatory Bowel Diseases 03/2012; · 4.86 Impact Factor